Kristine A Moore
Overview
Explore the profile of Kristine A Moore including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
389
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lackritz E, Ng L, Marques E, Rabe I, Bourne N, Staples J, et al.
Lancet Infect Dis
. 2025 Mar;
PMID: 40024263
The 2015-16 Zika virus epidemic emerged in the Americas and rapidly spread throughout the region and beyond, showing the epidemic potential of this mosquito-borne Orthoflavivirus and its capacity to cause...
2.
Ostrowsky J, Katzelnick L, Bourne N, Barrett A, Thomas S, Diamond M, et al.
Lancet Infect Dis
. 2025 Mar;
PMID: 40024262
The 2015-16 Zika virus epidemic in the Americas drew global attention to Zika virus infection as a cause of microcephaly and Guillain-Barré syndrome. The epidemic highlighted the urgent need for...
3.
Moore K, Ostrowsky J, Mehr A, Johnson R, Ulrich A, Moua N, et al.
Lancet Infect Dis
. 2024 Jul;
24(11):e696-e706.
PMID: 38964363
In 2016, WHO designated Lassa fever a priority disease for epidemic preparedness as part of the WHO Blueprint for Action to Prevent Epidemics. One aspect of preparedness is to promote...
4.
Moore K, Mehr A, Ostrowsky J, Ulrich A, Moua N, Fay P, et al.
Lancet Infect Dis
. 2024 Jul;
24(11):e707-e717.
PMID: 38964362
Nipah virus causes highly lethal disease, with case-fatality rates ranging from 40% to 100% in recognised outbreaks. No treatments or licensed vaccines are currently available for the prevention and control...
5.
Moore K, Leighton T, Ostrowsky J, Anderson C, Danila R, Ulrich A, et al.
Vaccine
. 2023 Mar;
41(13):2101-2112.
PMID: 36870874
Broadly protective coronavirus vaccines are an important tool for protecting against future SARS-CoV-2 variants and could play a critical role in mitigating the impact of future outbreaks or pandemics caused...
6.
Moore K, Osterholm M, Lackritz E, Poland G
Vaccine
. 2022 Sep;
40(42):6001-6003.
PMID: 36109277
No abstract available.
7.
Brosseau L, Escandon K, Ulrich A, Rasmussen A, Roy C, Bix G, et al.
Clin Infect Dis
. 2021 Oct;
75(1):e1195-e1201.
PMID: 34651164
The relationship between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) dose, infection, and coronavirus disease 2019 (COVID-19) outcomes remains poorly understood. This review summarizes the existing literature regarding this issue,...
8.
Moore K, Ostrowsky J, Kraigsley A, Mehr A, Bresee J, Friede M, et al.
Vaccine
. 2021 Oct;
39(45):6573-6584.
PMID: 34602302
Improved influenza vaccines are urgently needed to reduce the burden of seasonal influenza and to ensure a rapid and effective public-health response to future influenza pandemics. The Influenza Vaccines Research...
9.
Kraigsley A, Moore K, Bolster A, Peters M, Richardson D, Arpey M, et al.
Vaccine
. 2021 May;
39(25):3419-3427.
PMID: 33992439
Introduction: Despite considerable global burden of influenza, few low- and middle-income countries (LMICs) have national influenza vaccination programs. This report provides a systematic assessment of barriers to and activities that...
10.
Koff W, Schenkelberg T, Williams T, Baric R, McDermott A, Cameron C, et al.
Sci Transl Med
. 2021 Feb;
13(579).
PMID: 33536277
Development of safe and effective COVID-19 vaccines is a global priority and the best hope for ending the COVID-19 pandemic. Remarkably, in less than 1 year, vaccines have been developed...